[go: up one dir, main page]

WO2020246807A3 - Composition pharmaceutique pour le traitement du cancer, contenant un composé naphtoquinone - Google Patents

Composition pharmaceutique pour le traitement du cancer, contenant un composé naphtoquinone Download PDF

Info

Publication number
WO2020246807A3
WO2020246807A3 PCT/KR2020/007223 KR2020007223W WO2020246807A3 WO 2020246807 A3 WO2020246807 A3 WO 2020246807A3 KR 2020007223 W KR2020007223 W KR 2020007223W WO 2020246807 A3 WO2020246807 A3 WO 2020246807A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
treating cancer
cancer
naphthoquinone compound
nad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2020/007223
Other languages
English (en)
Korean (ko)
Other versions
WO2020246807A2 (fr
Inventor
이휘성
이은주
고인석
윤민혁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lmito Therapeutics Inc
Original Assignee
Lmito Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lmito Therapeutics Inc filed Critical Lmito Therapeutics Inc
Publication of WO2020246807A2 publication Critical patent/WO2020246807A2/fr
Publication of WO2020246807A3 publication Critical patent/WO2020246807A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour le traitement du cancer, contenant un composé naphtoquinone ou un sel pharmaceutiquement acceptable, un hydrate, un solvate, un énantiomère, un diastéréoisomère, un tautomère ou un promédicament de celui-ci, la composition augmentant le rapport de NAD+ et de NAD+/NADH par l'intermédiaire d'une activité par rapport à NQO1 in vivo, supprimant la production de lactate produite par glycolyse, qui est excessivement augmenté pendant le traitement métabolique des cellules cancéreuses, de manière à réduire la quantité de lactate devant être libérée dans un microenvironnement tumoral, ce qui améliore l'activité des cellules immunitaires et, par conséquent, permet aux cellules immunitaires activées d'éliminer les cellules cancéreuses, et ainsi la présente invention peut être utilisée dans le traitement du cancer.
PCT/KR2020/007223 2019-06-04 2020-06-03 Composition pharmaceutique pour le traitement du cancer, contenant un composé naphtoquinone Ceased WO2020246807A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0066241 2019-06-04
KR20190066241 2019-06-04

Publications (2)

Publication Number Publication Date
WO2020246807A2 WO2020246807A2 (fr) 2020-12-10
WO2020246807A3 true WO2020246807A3 (fr) 2021-01-21

Family

ID=73653026

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/007223 Ceased WO2020246807A2 (fr) 2019-06-04 2020-06-03 Composition pharmaceutique pour le traitement du cancer, contenant un composé naphtoquinone

Country Status (1)

Country Link
WO (1) WO2020246807A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080047972A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 나프토퀴논계 화합물 함유 장 표적용 함암 조성물
WO2018005279A1 (fr) * 2016-06-27 2018-01-04 Systems Oncology, Llc Polychimiothérapies
CN109481438A (zh) * 2018-11-24 2019-03-19 新乡医学院 2-氨基萘并[1,2-d]噻唑-4,5-二酮在治疗肿瘤药物中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080047972A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 나프토퀴논계 화합물 함유 장 표적용 함암 조성물
WO2018005279A1 (fr) * 2016-06-27 2018-01-04 Systems Oncology, Llc Polychimiothérapies
CN109481438A (zh) * 2018-11-24 2019-03-19 新乡医学院 2-氨基萘并[1,2-d]噻唑-4,5-二酮在治疗肿瘤药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUANG HUIDAN; YAN MING; CHEN JIANQIU; YUAN BIAO; CHEN GUITANG; CHENG SHUJIE; HUANG DECHUN; GAO ZHEN; CAO CHONGJIANG: "Identification ofortho-naphthoquinones as anti-AML agents by highly efficient oxidation of phenols", BIOORGANIC CHEMISTRY, vol. 86, 18 January 2019 (2019-01-18), pages 97 - 102, XP085657577, ISSN: 0045-2068, DOI: 10.1016/j.bioorg.2019.01.025 *
XIANG LI , JINLEI BIAN , NAN WANG , XUE QIAN , JING GU , TONG MU , JUN FAN , XIUWEN YANG , SHANGZHEN LI , TINGLING YANG , HAOPENG : "Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 24, no. 5, 16 January 2016 (2016-01-16), pages 1006 - 1013, XP029418885, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2016.01.024 *

Also Published As

Publication number Publication date
WO2020246807A2 (fr) 2020-12-10

Similar Documents

Publication Publication Date Title
MX2022015695A (es) Medicina de camptotecina con alta unidad de conexion hidrofila y conjugado de la misma.
WO2020102804A3 (fr) Combinaison pharmaceutique pour le traitement du cancer
NZ602675A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
ZA200802811B (en) Therapy for the treatment of disease
MX2023006883A (es) Metodos para tratar el cancer de prostata.
MX2023001671A (es) Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis.
WO2023122782A3 (fr) Indoles, indazoles et analogues apparentés pour inhiber yap/taz-tead
IL191796A0 (en) Combination of zd6474 and pemetrexed
CA2464758A1 (fr) Therapie combinant l'utilisation de zd6474 et d'un taxane
MX2022014192A (es) Metodos para tratar el cancer de prostata.
MX2024007932A (es) Spiros y analogos relacionados para inhibir yap/taz-tead.
MX2024011249A (es) Dosificacion no lineal de mirdametinib.
MX2025009374A (es) Compuesto que contiene trifluorometilsulfonilo
WO2023122783A8 (fr) Tétrahydropyrazolopyrimidines et analogues associés pour inhiber yap/taz-tead
ZA202500501B (en) Use of benzisoselenazole compound in preparation of drug for treatment of spinaglioma
WO2017181193A3 (fr) Procédés et composés permettant de stimuler la translecture de codons de terminaison prématurée
WO2021242844A8 (fr) Inhibiteurs de grk2 et leurs utilisations
WO2015035410A8 (fr) Traitement du cancer
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
WO2020246807A3 (fr) Composition pharmaceutique pour le traitement du cancer, contenant un composé naphtoquinone
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
AR074108A1 (es) Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
CR20200636A (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitorio para el tratamiento de una enfermedad parasitoria
WO2019241641A3 (fr) Méthodes de traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20817866

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20817866

Country of ref document: EP

Kind code of ref document: A2